Venture&Growth
Location
Wayne (PA), USA
Venture&Growth
All Portfolio items
See full Venture&Growth portfolio
US-based MedTech company developing a novel venous stent.
Vesper Medical is a medical device company dedicated to the development of a novel venous stent for the treatment of a variety of venous diseases. The company had achieved CE Mark and has initiated the VIVID trial in the US for FDA approval. Vesper was founded in 2016 as a spin-out of Intact Vascular.
In 2022, Royal Philips acquired 100% of the Vesper shares, providing Gilde with an attractive return within a three-year holding period.
More Vesper Medical news
Vesper Medical Announces First Enrollment in the VIVID Trial
Gilde Healthcare co-leads $37M financing of Vesper Medical to complete development of its Duo Venous Stent System
Venture&Growth
Purespring Therapeutics
Founded in 2020, Purespring is a pioneering London (UK)-based gene therapy company focused on transforming treatments for patients suffering from chronic kidney diseases. It is the first company to successfully treat kidney disease by targeting the podocyte, a specialised cell
Venture&Growth
Acacia Pharma
Belgian Therapeutics company commercializing supportive care products to treat side effects of medical procedures.
Venture&Growth
SpliceBio
SpliceBio is a Spanish therapeutics company addressing the key limitations of current gene therapy. It harnesses its proprietary Protein Splicing platform to develop next-generation gene therapies, based on engineered inteins pioneered at the Muir Lab at Princeton University. The company
